FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2391007907> ?p ?o ?g. }

• W2391007907 endingPage "S380" @default.
• W2391007907 startingPage "S380.2" @default.
• W2391007907 abstract "<h3></h3> Statins as a class are well tolerated. We assessed acceptability, efficacy, and safety of rosuvastatin in 57 euthyroid patients with primary high LDL cholesterol (LDLC) who, serially, could not tolerate most other statins or cholesterol-lowering drugs, primarily because of myocitis. Of the 57 patients, 44 could not tolerate atorvastatin, 27 simvastatin, 15 pravastatin, 7 fluvastatin, 2 lovastatin, 1 Vytorin, 10 WelChol, 5 Zetia, 2 TriCor, and 2 Niaspan. Rosuvastatin (5 mg/day)-diet was given to 24 patients (3 men, 21 women, 21 white, 3 black, 3 type 2 diabetics, mean ± SD age 61 ± 9 years, BMI 31.7 ± 4.2, LDLC 179 ± 32 mg/dL). On rosuvastatin 5 mg-diet for a median of 5 months, weight fell 3.0 ± 7.7 lb (<i>p</i> = .016), LDLC fell 76 ± 35 mg/dL (<i>p</i> < .0001) to 103 ± 31 mg/dL, with median percent change -47%. Adjusted for changes in body weight, decrements in LDLC remained significant, LS mean ± SE -75 ± 8 mg/dL, p < .0001. None of the 24 patients discontinued the 5 mg rosuvastatin, muscle symptoms were minor to absent, and there were no untoward changes in liver function tests ($ 3 times the laboratory upper normal limit), or in CPK ($ 10 times the laboratory upper normal limit). Rosuvastatin (10 mg/day) was given to 33 patients, 16 men, 17 women, 31 white, 1 black, 1 other, 9 smokers, 4 type 2 diabetics, mean ± SD age 59 ± 10 years, BMI 31.1 ± 5.2, and LDLC 178 ± 53 mg/dL. On therapy for a median of 11 months, body weight fell 3.1 ± 6.8 lb (p = .014), LDLC fell 80 ± 49 mg/dL (p < .0001) to 96 ± 38 mg/dL, median percent change -48%. Adjusted for body weight change, decrements in LDLC remained significant, LS mean ± SE -82 ± 11 mg/dL, p < .0001. None of the 33 patients discontinued the 10 mg rosuvastatin, muscle symptoms were minor to absent, and there were no untoward changes in liver function tests ($ 3 times the laboratory upper normal limit), or in CPK ($ 10 times the laboratory upper normal limit). Since rosuvastatin is not metabolized by the 3A4 isoenzyme of the cytochrome P450 enzyme system and is < 10% metabolized by the 2C9 isoenzyme, we speculate that its acceptability, efficacy, and safety in hypercholesterolemic patients unable to tolerate other statins are related to reduced interactions with other drugs known to inhibit CYP 450 enzymes. By contrast, atorvastatin, lovastatin, and simvastatin are metabolized through the 3A4 pathway and fluvastatin through 2C9, common pathways for many other drugs, facilitating drug-drug interactions, which may be expressed clinically as muscle symptoms, leading to discontinuance of the statin. Rosuvastatin9s LDLC lowering potency often facilitates reaching LDLC goals by use of low doses, 5 or 10 mg/day." @default.
• W2391007907 created "2016-06-24" @default.
• W2391007907 creator A5040347048 @default.
• W2391007907 creator A5040892752 @default.
• W2391007907 creator A5045925897 @default.
• W2391007907 creator A5070841915 @default.
• W2391007907 creator A5073047245 @default.
• W2391007907 creator A5075647523 @default.
• W2391007907 creator A5079058910 @default.
• W2391007907 creator A5086225326 @default.
• W2391007907 date "2006-03-01" @default.
• W2391007907 modified "2023-09-26" @default.
• W2391007907 title "41 ROSUVASTATIN ACCEPTABILITY, EFFICACY, AND SAFETY IN HYPERCHOLESTEROLEMIC PATIENTS UNABLE TO TOLERATE OTHER STATINS." @default.
• W2391007907 doi "https://doi.org/10.2310/6650.2005.x0015.119" @default.
• W2391007907 hasPublicationYear "2006" @default.
• W2391007907 type Work @default.
• W2391007907 sameAs 2391007907 @default.
• W2391007907 citedByCount "0" @default.
• W2391007907 crossrefType "journal-article" @default.
• W2391007907 hasAuthorship W2391007907A5040347048 @default.
• W2391007907 hasAuthorship W2391007907A5040892752 @default.
• W2391007907 hasAuthorship W2391007907A5045925897 @default.
• W2391007907 hasAuthorship W2391007907A5070841915 @default.
• W2391007907 hasAuthorship W2391007907A5073047245 @default.
• W2391007907 hasAuthorship W2391007907A5075647523 @default.
• W2391007907 hasAuthorship W2391007907A5079058910 @default.
• W2391007907 hasAuthorship W2391007907A5086225326 @default.
• W2391007907 hasConcept C126322002 @default.
• W2391007907 hasConcept C126894567 @default.
• W2391007907 hasConcept C134018914 @default.
• W2391007907 hasConcept C2776329913 @default.
• W2391007907 hasConcept C2776839432 @default.
• W2391007907 hasConcept C2777482532 @default.
• W2391007907 hasConcept C2778163477 @default.
• W2391007907 hasConcept C2778417548 @default.
• W2391007907 hasConcept C2779519902 @default.
• W2391007907 hasConcept C2780499067 @default.
• W2391007907 hasConcept C71924100 @default.
• W2391007907 hasConcept C90924648 @default.
• W2391007907 hasConceptScore W2391007907C126322002 @default.
• W2391007907 hasConceptScore W2391007907C126894567 @default.
• W2391007907 hasConceptScore W2391007907C134018914 @default.
• W2391007907 hasConceptScore W2391007907C2776329913 @default.
• W2391007907 hasConceptScore W2391007907C2776839432 @default.
• W2391007907 hasConceptScore W2391007907C2777482532 @default.
• W2391007907 hasConceptScore W2391007907C2778163477 @default.
• W2391007907 hasConceptScore W2391007907C2778417548 @default.
• W2391007907 hasConceptScore W2391007907C2779519902 @default.
• W2391007907 hasConceptScore W2391007907C2780499067 @default.
• W2391007907 hasConceptScore W2391007907C71924100 @default.
• W2391007907 hasConceptScore W2391007907C90924648 @default.
• W2391007907 hasIssue "2" @default.
• W2391007907 hasLocation W23910079071 @default.
• W2391007907 hasOpenAccess W2391007907 @default.
• W2391007907 hasPrimaryLocation W23910079071 @default.
• W2391007907 hasRelatedWork W138064960 @default.
• W2391007907 hasRelatedWork W1983373805 @default.
• W2391007907 hasRelatedWork W1999506027 @default.
• W2391007907 hasRelatedWork W2074324898 @default.
• W2391007907 hasRelatedWork W2100240490 @default.
• W2391007907 hasRelatedWork W2109107848 @default.
• W2391007907 hasRelatedWork W2605564895 @default.
• W2391007907 hasRelatedWork W2904158935 @default.
• W2391007907 hasRelatedWork W4243799561 @default.
• W2391007907 hasRelatedWork W71995819 @default.
• W2391007907 hasVolume "54" @default.
• W2391007907 isParatext "false" @default.
• W2391007907 isRetracted "false" @default.
• W2391007907 magId "2391007907" @default.
• W2391007907 workType "article" @default.